Teva Pharmaceutical Industries stock
Price history
+70.84% over the period1 year: from $24.59 (November 17, 2025) to $42.01 (November 17, 2026), +70.84%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $42.01 |
| October 30, 2026 | $42.09 |
| September 30, 2026 | $39.60 |
| August 31, 2026 | $36.05 |
| July 31, 2026 | $35.01 |
| June 30, 2026 | $33.88 |
| May 29, 2026 | $35.32 |
| April 30, 2026 | $35.07 |
| March 31, 2026 | $30.12 |
| February 27, 2026 | $33.86 |
| January 30, 2026 | $34.08 |
| December 31, 2025 | $31.21 |
| November 28, 2025 | $26.89 |
| November 17, 2025 | $24.59 |
At a glance
The company
Develops, manufactures and distributes generic medicines, biopharmaceutical products and specialty drugs for central nervous system, respiratory and oncology conditions
Latest results
Quarter to September 30, 2026 · EPS $0.86 (estimate $0.72)
Next event
TickerLandia's take on Teva Pharmaceutical Industries
- Pricier than similar companies: trailing 12-month P/E 99 vs 41 (+142%) in a group of 9.
- Strong point: Market momentum (89/100 in its group). Weak point: Earnings stability (9/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−4.38% from the 52-week high
Analysts · 15 analysts
Average target$50.29+18.01% vs. price
Buy 13 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: Teva Pharmaceutical Industries
Compared with similar companies: very low earnings stability, very strong momentum, and very low financial strength.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage56
How much it costs relative to what it produces.
Metric Value Position in group EV/EBITDA 14.7 43 P/E (trailing 12 months) 103.5 96 Forward P/E 14.3 21 Price/book 6.51 78 Price/sales 3.01 43 Profitabilitylow30
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 19.8% 53 ROE 6.7% 22 Gross margin 53.5% 27 Net margin 2.9% 14 ROA 5.4% 35 Earnings stabilityvery low9
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 11.0% 9 Loss-making yearscounts in reverse: lower means more earnings stability 3 of 5 annual reports 9 Growthlow20
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) −46.00% 18 Revenue growth (year over year) −1.90% 7 Average revenue growth (3 years) +4.96% 36 Financial strengthvery low11
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.76 15 Current ratio 0.95 6 Interest coverage 4.31 17 Debt/equitycounts in reverse: lower means more financial strength 2.13 7 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumvery strong89
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +67.53% 95 Distance from 200-day average +21.13% 90 Relative strength (3 months) +19.20% 90 Relative strength (6 months) +21.63% 81 Risklow39
How much the price swings.
Metric Value Position in group Volatility (60 days) 30.3% 40 Maximum drawdown (12 months) 21.8% 32 Beta (1 year) 0.58 45
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Teva Pharmaceutical Industries is pricier than similar companies
Teva Pharmaceutical Industries's P/E (trailing 12 months): 99.0, +142% against the median of a group of 9 similar companies (40.9).
Compared with 9 similar companies
| Metric | Teva Pharmaceutical Industries | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 99.0 | High | |
| Forward P/E | 13.6 | Low | |
| Operating margin | 19.8% | Middle | |
| ROE | 6.7% | Middle | |
| Debt/equity | 2.13 | High |
Grey band: the middle half of the group; tick: the median; dot: Teva Pharmaceutical Industries. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$4.4B
Latest quarter · Q3 2026
Net income
$233M
Latest quarter · Q3 2026
Quarterly net margin
5.3%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $49.67B
- P/E
- 99.0
- EPS
- $0.43
- Volume
- 7.46M
- Daily trading
- €280.25M
How Teva Pharmaceutical Industries is changing
All resultsRevenue grew 0.7% a year on average over the last 5 years
Operating margin rose from −14.7% to 12.5%
Shares outstanding up 6.2% in 5 years
Returns
Teva Pharmaceutical Industries returns with dividends
$1,000 invested in Teva Pharmaceutical Industries 5 years ago, on November 17, 2021, would be worth $4,586 today with dividends reinvested: +358.62% in total, +35.62% per year. On price alone it would be $4,586 (+358.62%).
| Period | Teva Pharmaceutical Industries | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +1.69% | −3.17% | $1,017 |
| 6 months | +24.29% | +0.11% | $1,243 |
| Year to date | +34.60% | +8.34% | $1,346 |
| 1 year | +70.84% | +11.15% | $1,708 |
| 3 years | +364.20% | +64.30% | $4,642 |
| 5 years | +358.62% | +58.18% | $4,586 |
| 10 years | +11.91% | +239.10% | $1,119 |
Over the last 6 months it has done better than 62% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Teva Pharmaceutical Industries: technical analysis
Teva Pharmaceutical Industries is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 40.8% below its highest close since January 2, 1990 ($72.00, July 27, 2015).
- Trend
- Upward
- RSI (14 sessions)
- 56
- Between 30 and 70
- vs 200-session average
- +21.15%
Support and resistance
Price areas where Teva Pharmaceutical Industries has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$42.62
- Support$41.95−1.57%2 touches, last on October 19, 2026
- Support$38.31−10.12%3 touches, last on October 8, 2026
- Support$37.17−12.79%2 touches, last on May 7, 2026
Volatility and risk
Over the last year it has moved less than the S&P 500.
- Beta (1 year) vs S&P 500
- 0.61
- Volatility (60 sessions, annualised)
- 30.2%
- Largest fall in the last year
- −21.79%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Teva Pharmaceutical Industries: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Teva Pharmaceutical Industries has been December: +4.42% on average, positive in 23 years out of 36. The weakest has been March: −1.42% on average, positive in 18 years out of 37. November, the current month, has been positive in 23 years out of 36 (+4.25% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +4.21% | +5.32% | 23 of 36 |
| February | +0.91% | −0.65% | 17 of 37 |
| March | −1.42% | −0.90% | 18 of 37 |
| April | +0.68% | −1.16% | 15 of 37 |
| May | +2.49% | +4.48% | 22 of 37 |
| June | −0.25% | −0.12% | 18 of 37 |
| July | +2.50% | +1.08% | 21 of 37 |
| August | −0.21% | −0.60% | 17 of 37 |
| September | +0.81% | +1.06% | 19 of 37 |
| October | −0.54% | −0.49% | 17 of 37 |
| November | +4.25% | +4.75% | 23 of 36 |
| December | +4.42% | +4.16% | 23 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Teva Pharmaceutical Industries and its competitors
Operating from Tel Aviv-Yafo, Israel, since its founding in 1901, the group works in generic medicines and biopharmaceutical products sold across the United States, Europe, Israel and other international markets. Its range covers tablets, capsules, injectables, inhalants, transdermal patches and creams, as well as sterile products, hormones and high-potency drugs. Among its brands are COPAXONE for multiple sclerosis, AUSTEDO for tardive dyskinesia, UZEDY for schizophrenia, AJOVY for migraine prevention, QVAR RediHaler for asthma and the over-the-counter SUDOCREM.
- Headquarters
- Tel Aviv-Yafo, Israel
- Employees
- 31,173
- Founded
- 1901
- Chief executive
- Richard Francis
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Teva Pharmaceutical IndustriesTEVA | $49.67B | 19.8% | 99.0 | +24.29% |
| ZoetisZTS | $33.92B | 37.9% | 14.1 | +12.48% |
| United TherapeuticsUTHR | $25.04B | 39.4% | 22.2 | +2.73% |
| ViatrisVTRS | $23.58B | — | — | +24.09% |
| Neurocrine BiosciencesNBIX | $16.73B | 26.6% | 24.5 | +4.73% |
| Hims & Hers HealthHIMS | $4.13B | -6.4% | — | −29.94% |
Same industry or related industries, similar size. Compare Teva Pharmaceutical Industries with its competitors · Full profile
More on Teva Pharmaceutical Industries
- Teva Pharmaceutical Industries revenue and financials
- Teva Pharmaceutical Industries valuation
- Teva Pharmaceutical Industries stock return
- Teva Pharmaceutical Industries employees, headquarters and business
